Company Profile

Ra Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapeutics for the treatment of serious diseases that are caused by excessive or uncontrolled activation of the complement system. It is developing its lead product candidate, RA101495, a self-administered subcutaneous (SC) injection. RA101495 is injected into the tissue under the skin for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). The Company is also developing RA101495 to treat other debilitating complement-mediated diseases such as generalized myasthenia gravis (gMG) and lupus nephritis (LN). It also focuses on discovery and preclinical programs targeting selective inhibition of other uncontrolled complement pathway factors to treat a variety of ophthalmic, renal and inflammatory diseases. The Company uses its Extreme Diversity platform, macrocyclic peptide chemistry technology which produces synthetic macrocyclic peptides.

Employees

Sector

Biotechnology & Medical Research

More about the company

03/04/20	Ra Pharmaceuticals, Inc.(NasdaqGM:RARX) dropped from S&P TMI Index	CI
03/04/20	Ra Pharmaceuticals, Inc.(NasdaqGM:RARX) dropped from S&P Global BMI Index	CI
03/04/20	Ra Pharmaceuticals, Inc.(NasdaqGM:RARX) dropped from S&P Biotechnology Select Industry Index	CI
02/04/20	UCB SA completed the acquisition of Ra Pharmaceuticals, Inc. from Douglas A. Treco, New Enterprise Associates 13, L.P. managed by New Enterprise Associates and RA Capital Healthcare Fund, L.P managed by Ra Capital Management, LLC and others.	CI
27/02/20	Ra Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019	CI
18/02/20	Ra Pharmaceuticals, Inc. Announces Publication of Zilucoplan Phase 2 gMG Trial Results in JAMA Neurology	CI
22/01/20	Ra Pharmaceuticals, Inc. Announces Clearance of IND Application for the HEALEY ALS Platform Trial	CI
04/12/19	Ra Pharmaceuticals, Inc. Announces Dosing of First Patient in Phase 2 Clinical Trial of Zilucoplan for IMNM	CI
07/11/19	Ra Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	CI
10/10/19	UCB SA entered into an agreement to acquire Ra Pharmaceuticals, Inc. from Douglas A. Treco, New Enterprise Associates 13, L.P. managed by New Enterprise Associates and Ra Capital Management, LLC and others for $2.3 billion.	CI
02/10/19	Ra Pharmaceuticals, Inc. Announces Dosing of First Patient in Global Phase 3 Pivotal Study of Zilucoplan for GMG	CI
24/08/19	Certain Common Stock of Ra Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 24-AUG-2019.	CI
24/08/19	Certain Stock Options of Ra Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 24-AUG-2019.	CI

02/04/20	RA PHARMACEUTICALS, INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
31/03/20	RA PHARMACEUTICALS, INC. : Other Events (form 8-K)	AQ
16/03/20	RA PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	AQ
02/03/20	Ra Pharmaceuticals : Supports 13th Annual Rare Disease Day and Joins Global Movement to Raise Awareness for Rare Diseases	AQ
29/02/20	RA PHARMACEUTICALS, INC. : Other Events (form 8-K)	AQ

11/10/19	UCB : poursuit sur sa lancée, un broker en soutien
10/10/19	Wall Street : en hausse avant la réunion Trump/Liu-He
10/10/19	Wall Street : ouverture hésitante en vue
10/10/19	USA-Les valeurs à suivre à Wall Street
10/10/19	Ra Pharmaceuticals : vers une OPA d'UCB à 48 dollars

Date	Insider	Type	Main position	Quantity	% Market Cap.
4/2/20 A	John C. King	Issuer sale	Executive/Senior Manager	338,481	0.7152%
4/2/20 A	RA Capital Management LP	Issuer sale	Company	4,903,260	10.3599%
4/2/20 A	Alonso Ricardo	Issuer sale	Chief Technology Officer	279,168	0.5898%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
RA PHARMACEUTICALS, INC.	-.--%	+0.91%	-	-	2.27B
WUXI APPTEC CO., LTD.	+0.34%	+1.12%	+34.75%	+61.06%	64.38B
ARGENX SE	+0.98%	+2.68%	+12.25%	+82.98%	56.16B
LONZA GROUP AG	+1.75%	+2.01%	+13.30%	+103.69%	54.16B
IQVIA HOLDINGS INC.	-1.43%	-1.17%	+26.27%	+52.86%	45.33B
BEONE MEDICINES AG	-0.48%	-2.80%	+18.01%	+117.99%	42.25B
REVOLUTION MEDICINES, INC.	+0.82%	+1.37%	+227.94%	+922.41%	40.78B
GENMAB A/S	-2.07%	+42.73%	+103.77%	+88.74%	33.8B
CELLTRION, INC.	-0.26%	-2.57%	+12.55%	+45.18%	32.25B
WUXI BIOLOGICS (CAYMAN) INC.	-1.64%	-3.41%	+20.94%	-12.40%	23.57B
Average	-0.22%	+4.50%	+52.20%	+162.50%	43.63B
Weighted average by Cap.	-0.00%	+3.60%	+49.15%	+161.38%

Ra Pharmaceuticals, Inc. Stock

Stocks

US74933V1089

Biotechnology & Medical Research

Latest news: Ra Pharmaceuticals, Inc.

Press Releases: Ra Pharmaceuticals, Inc.

News in other languages: Ra Pharmaceuticals, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Company Profile